COMPANY

Fibralign Corporation

HQ: Union City, CA source · fibralignbio.com ↗ · West Coast

Also known as FibrAlign · 8 sources

Fibralign’s patented Nanoweave® technology provides the means to induce self-assembly of molecular type I collagen to replicate native tissue scaffold outside of the body. From company website Source · Oct 12, 2026

Keywords: lymphedema regenerative medicine breast cancer Edema BioBridge® Collagen Matrix

Location: Union City, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)6NIH grants

Timeline

Nov 1, 2023 Trial start Not phased (device or behavioral study): Surgical Evaluation for Upper Extremity Lymphedema (BioBridge) source ↗
Oct 26, 2020 Trial start Not phased (device or behavioral study): LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05695924	Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)	Not phased (device or behavioral study)	Recruiting	Nov 1, 2023	Oct 1, 2025 (estimated)
NCT04606030	LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)	Not phased (device or behavioral study)	Recruiting	Oct 26, 2020	Oct 30, 2025 (estimated)

NIH awards 6

Annual award amounts. Total $3.0M.

Aug 16, 2021 NIH award 5R44CA203608-06 FY2021: $682,266 awarded for that fiscal year; activity R44 (SBIR); PI PAUKSHTO, MICHAEL VITOLDOVICH; recipient as written: FIBRALIGN CORPORATION, UNION CITY, CA. Prospective evaluation of a source ↗
Aug 31, 2020 NIH award 5R44CA203608-05 FY2020: $32,935 awarded for that fiscal year; activity R44 (SBIR); PI PAUKSHTO, MICHAEL VITOLDOVICH; recipient as written: FIBRALIGN CORPORATION, UNION CITY, CA. Prospective evaluation of a source ↗
Sep 12, 2019 NIH award 5R44CA203608-04 FY2019: $252,861 awarded for that fiscal year; activity R44 (SBIR); PI PAUKSHTO, MICHAEL VITOLDOVICH; recipient as written: FIBRALIGN CORPORATION, UNION CITY, CA. Prospective evaluation of a source ↗
Aug 6, 2019 NIH award 3R44CA203608-03S1 FY2019: $1,695 awarded for that fiscal year; activity R44 (SBIR); PI PAUKSHTO, MICHAEL VITOLDOVICH; recipient as written: FIBRALIGN CORPORATION, UNION CITY, CA. Prospective evaluation of a source ↗
Aug 30, 2018 NIH award 5R44CA203608-03 FY2018: $998,174 awarded for that fiscal year; activity R44 (SBIR); PI PAUKSHTO, MICHAEL VITOLDOVICH; recipient as written: FIBRALIGN CORPORATION, UNION CITY, CA. Prospective evaluation of a source ↗
Aug 18, 2017 NIH award 2R44CA203608-02A1 FY2017: $997,783 awarded for that fiscal year; activity R44 (SBIR); PI PAUKSHTO, MICHAEL VITOLDOVICH; recipient as written: FIBRALIGN CORPORATION, UNION CITY, CA. Prospective evaluation of source ↗